AEGiS-GMHC: Oral Alpha Interferon

Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Oral Alpha Interferon

GMHC Treatment Issues, No. 43; Volume 4 Number 3 -- May 22, 1990
Kevin Armington

The announcement of dramatic improvement in Kenyan patients taking an oral form of alpha interferon has generated intense excitement. While we would like to accept these results at face value, it would irresponsible to do so without independent confirmation of this drug's effect. John James wrote an excellent assessment of what is known about the Kenyan trial in issue 101 of AIDS Treatment News. This article points out that a substantial number of trial participants began the study with T4 cell counts above 700.

A number of buyers' clubs in the U. S. are now selling alpha interferon ready to be taken orally, either as a liquid or on wafers. In Fort Lauderdale, the PWA Health Alliance is running a loosely defined clinical trial. For those who live in the area, trial costs are $25; participants from outside the area, the charge is $55. For more information, call 305-763-7723. In New York, the PWA Health Group is selling alpha interferon wafers containing 150 international units of Wellferon, a naturally- derived interferon made by Burroughs-Wellcome. A three-week supply of wafers costs $21. It is suggested that individuals only buy three weeks' worth at a time. For proper storage, keep the wafers cold and dry. The Health Group suggests storing the wafers in a zip-lock bag or a jar. Wafers should be held under the tongue for several minutes and then swallowed. It should be noted that the side effects of alpha interferon taken in this from are unknown. It is possible that people who take it may experience nausea, vomiting or flu-like symptoms. In addition, potential interactions with other drugs are unknown.

A study of oral alpha interferon will be conducted at Mt. Sinai Hospital, by Dr. Joseph Hassett. Thirty-five patients will be recruited for a placebo-controlled trial. (There is already a waiting list.) Participants must have between 150-350 T4 cell counts. No patients with KS will be admitted in the study. For more information, call (212) 241-6331.

900522
GM040304

Copyright © 1990 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .